IRIS
BERGAMASCHI, MICAELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.214
Totale 1.214
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 1.214
Totale 1.214
Salva come PNG Salva come JPEG
Città #
Genova 879
Rapallo 180
Genoa 152
Bordighera 2
Vado Ligure 1
Totale 1.214
Salva come PNG Salva come JPEG
Nome #
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 168
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 164
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 110
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 102
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 101
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 98
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 96
Un cas de cryptococcose cutanèe primitive sans diffusion systemique chez un patient immunodeprimé 87
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 77
Bendamustine-rituximab (BR) combined therapy for treatment of immuno-mediated neuropathies associated with hematologic malignancy. 60
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 58
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 51
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 46
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 37
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 27
Totale 1.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.462
article - articoli 4.232
book - libri 0
conference - conferenze 230
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.924
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020409 30 3 11 32 41 49 57 42 45 53 33 13
2020/2021219 7 22 7 24 21 14 34 22 14 33 14 7
2021/2022179 8 2 5 22 3 14 3 38 18 12 12 42
2022/2023217 21 25 3 24 35 36 0 18 31 3 20 1
2023/2024115 10 10 3 19 10 22 5 14 3 1 2 16
2024/20256 6 0 0 0 0 0 0 0 0 0 0 0
Totale 1.282